For anyone in Teasc trying to locate CJC-1295, the foundational reality is that this compound is distributed via specialist online vendors. This matters because CJC-1295 quality varies dramatically across the market — from verified research-grade material to material with significant impurity issues — and the vendor determines everything about the product. What reliably differentiates top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for peptide identity confirmation, and endotoxin testing for safety screening. This guide gives Teasc researchers the methodology to assess vendor quality rigorously and source research-grade CJC-1295 with confidence.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Teasc comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Quality CJC-1295 sourcing begins with a useful first test: does this vendor publish batch-specific COAs proactively? Vendors who do are signalling genuine quality commitment. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Community reputation in research forums is a complementary signal to COA verification — vendors with multi-year positive track records have earned that standing through repeat quality delivery. The powdered lyophilised form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations degrade within weeks even when refrigerated.
Order CJC-1295 — ships to Teasc
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the known safety profile is based on preclinical evidence rather than regulated clinical data. Storage requirements for CJC-1295: lyophilised powder at −20°C, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with bacteriostatic water. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no cost saving makes omitting this acceptable. PubMed and bioRxiv represent the most comprehensive research databases for CJC-1295 research; focus on peer-reviewed publications with documented compound quality over unreviewed preprints or forum reports.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
